See more : Sonae, SGPS, S.A. (SON.LS) Income Statement Analysis – Financial Results
Complete financial analysis of Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Beijing Tong Ren Tang Chinese Medicine Company Limited, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Global Synergy Acquisition Corp. (GSAQU) Income Statement Analysis – Financial Results
- Centerspace (CSR) Income Statement Analysis – Financial Results
- Takeda Pharmaceutical Company Limited (TKPHF) Income Statement Analysis – Financial Results
- Cochlear Limited (CHEOF) Income Statement Analysis – Financial Results
- SENA J Property Public Company Limited (SENAJ.BK) Income Statement Analysis – Financial Results
Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF)
About Beijing Tong Ren Tang Chinese Medicine Company Limited
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products to wholesalers and individuals. The company operates through three segments: Hong Kong, Mainland China, and Overseas. It also offers Chinese medical consultation and treatment services. The company operates 23 retail outlets in Hong Kong and 46 retail outlets in other countries and regions in Asia, Oceania, North America, and Europe. It markets its products under the Tong Ren Tang brand. The company was founded in 1669 and is based in Wan Chai, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 195.29M | 221.60M | 199.55M | 169.64M | 183.86M | 193.36M | 161.95M | 139.85M | 125.22M |
| Cost of Revenue | 61.18M | 82.58M | 57.02M | 48.31M | 55.43M | 57.97M | 47.02M | 39.27M | 39.29M |
| Gross Profit | 134.12M | 139.02M | 142.53M | 121.33M | 128.44M | 135.39M | 114.92M | 100.58M | 85.93M |
| Gross Profit Ratio | 68.67% | 62.73% | 71.43% | 71.52% | 69.85% | 70.02% | 70.96% | 71.92% | 68.62% |
| Research & Development | 1.56M | 985.55K | 1.45M | 1.22M | 1.73M | 2.37M | 1.23M | 551.13K | 665.15K |
| General & Administrative | 179.03M | 154.46M | 155.31M | 135.53M | 21.15M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 231.26M | 187.22M | 186.37M | 168.92M | 21.93M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 53.68M | 35.37M | 42.28M | 37.04M | 43.46M | 44.13M | 36.67M | 32.50M | 27.29M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -27.08K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 55.24M | 36.36M | 43.72M | 38.29M | 45.19M | 46.50M | 37.90M | 33.05M | 27.95M |
| Cost & Expenses | 116.40M | 118.94M | 100.74M | 86.60M | 100.62M | 104.46M | 84.92M | 72.32M | 67.25M |
| Interest Income | 72.88M | 2.64M | 561.26K | 2.79M | 5.57M | 2.99M | 1.71M | 1.02M | 1.13M |
| Interest Expense | 5.98M | 596.65K | 603.58K | 554.56K | 539.93K | 2.43K | 4.09K | 5.55K | 27.74K |
| Depreciation & Amortization | 82.51M | 9.66M | 8.97M | 10.07M | 10.17M | 3.87M | 3.40M | 3.05M | 2.93M |
| EBITDA | 89.40M | 112.32M | 107.78M | 99.19M | 93.42M | 95.95M | 80.43M | 70.58M | 60.90M |
| EBITDA Ratio | 45.78% | 50.69% | 54.01% | 54.88% | 50.81% | 47.98% | 49.66% | 50.47% | 48.63% |
| Operating Income | 79.93M | 102.66M | 98.80M | 83.03M | 83.25M | 88.89M | 77.03M | 67.54M | 57.97M |
| Operating Income Ratio | 40.93% | 46.33% | 49.51% | 48.95% | 45.28% | 45.97% | 47.56% | 48.29% | 46.30% |
| Total Other Income/Expenses | 8.54M | 723.30M | 974.93K | 602.86M | 5.46M | 631.76M | 534.47M | 464.24M | 1.10M |
| Income Before Tax | 88.48M | 105.93M | 99.78M | 88.57M | 88.71M | 92.08M | 78.16M | 68.89M | 59.48M |
| Income Before Tax Ratio | 45.30% | 47.80% | 50.00% | 52.21% | 48.25% | 47.62% | 48.26% | 49.26% | 47.50% |
| Income Tax Expense | 12.44M | 17.24M | 16.27M | 15.22M | 14.42M | 15.27M | 13.49M | 11.92M | 10.59M |
| Net Income | 540.39M | 82.68M | 77.94M | 69.96M | 71.37M | 74.17M | 62.68M | 54.21M | 45.71M |
| Net Income Ratio | 276.71% | 37.31% | 39.06% | 41.24% | 38.82% | 38.36% | 38.70% | 38.76% | 36.50% |
| EPS | 0.08 | 0.10 | 0.09 | 0.08 | 0.09 | 0.09 | 0.07 | 0.06 | 0.05 |
| EPS Diluted | 0.08 | 0.10 | 0.09 | 0.08 | 0.09 | 0.09 | 0.07 | 0.06 | 0.05 |
| Weighted Avg Shares Out | 837.10M | 837.10M | 837.10M | 837.10M | 837.10M | 837.10M | 837.10M | 837.10M | 835.99M |
| Weighted Avg Shares Out (Dil) | 837.10M | 837.10M | 837.10M | 837.10M | 837.10M | 837.10M | 837.10M | 837.10M | 835.99M |
Source: https://incomestatements.info
Category: Stock Reports